interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Tazarotene

Generic competition · all medicines · read 12 November 2026

Is there a generic of Tazarotene, and who makes it?

Tazarotene appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 4 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 5.6 and 25.3 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Tazarotene4 dosage-form groups in the Orange Book
4generic makers listed
  1. Tazarotene appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 4 generic makers listed as marketed across them.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 5.6 and 25.3 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Cream, Topical

Four or more generic makers listed

Brand listed as marketed: Avage and Tazorac. 4 generic makers with 5 generic products listed as marketed; the first generic approval is dated 3 April 2017.

200020052010201520202025203004brand 2000Sun Pharma Canada Inc, first approval 3 April 2017Cosette Pharmaceuticals Nc Laboratories Llc, first approval 22 December 2017Padagis Israel Pharmaceuticals Ltd, first approval 15 July 2024Solaris Pharma Corp, first approval 24 November 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Sun Pharma Canada Inc3 April 20171
Cosette Pharmaceuticals Nc Laboratories Llc22 December 20172
Padagis Israel Pharmaceuticals Ltd15 July 20241
Solaris Pharma Corp24 November 20251

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Gel, Topical

One to three generic makers listed

Brand listed as marketed: Tazorac. 3 generic makers with 6 generic products listed as marketed; the first generic approval is dated 13 September 2022.

1995200020052010201520202025203003brand 1997Cosette Pharmaceuticals Nc Laboratories Llc, first approval 13 September 2022Solaris Pharma Corp, first approval 20 March 2023Padagis Israel Pharmaceuticals Ltd, first approval 25 April 2023data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Cosette Pharmaceuticals Nc Laboratories Llc13 September 20222
Solaris Pharma Corp20 March 20232
Padagis Israel Pharmaceuticals Ltd25 April 20232

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Lotion, Topical

Brand listed, no generic listed as marketed

Brand listed as marketed: Arazlo. No generic is listed as marketed (1 generic product listed as discontinued).

20152020202520302035204001brand 2019data datePatent 11679116 listed to expire 6 June 2036Patent 11311482 listed to expire 11 May 2038Patent 12128137 listed to expire 11 May 2038
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 6 June 2036Patent 11679116 drug product
  • 11 May 2038Patent 11311482
  • 11 May 2038Patent 12128137 drug product

Aerosol, Foam, Topical

Brand listed, no generic listed as marketed

Brand listed as marketed: Fabior. No generic is listed as marketed.

2010201520202025203001brand 2012data datePatent 10568859 listed to expire 24 February 2030Patent 10688071 listed to expire 24 February 2030Patent 8808716 listed to expire 24 February 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 24 February 2030Patent 10568859 drug product
  • 24 February 2030Patent 10688071 drug product
  • 24 February 2030Patent 8808716 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.